<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167725</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000681540</org_study_id>
    <secondary_id>WRAMC-8214</secondary_id>
    <nct_id>NCT01167725</nct_id>
  </id_info>
  <brief_title>Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer</brief_title>
  <official_title>Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Heating mitomycin C to&#xD;
      several degrees above normal body temperature and infusing it into the area around the tumor&#xD;
      may kill more tumor cells. Giving mitomycin C after surgery may kill any remaining tumor&#xD;
      cells. It is not yet known whether standard therapy is more effective with or without surgery&#xD;
      followed by mitomycin C.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying standard therapy with or without surgery&#xD;
      and mitomycin C in treating patients with advanced limited peritoneal dissemination of colon&#xD;
      cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the overall survival (OS) of patients with advanced limited peritoneal&#xD;
           dissemination of colon adenocarcinoma treated with systemic therapy with vs without&#xD;
           cytoreduction surgery and hyperthermic intraperitoneal mitomycin C.&#xD;
&#xD;
        -  To compare the relative OS at 1 year of patients treated with these regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the progression-free survival (PFS) of patients treated with these regimens.&#xD;
&#xD;
        -  To compare the relative PFS at 1 year of patients treated with these regimens.&#xD;
&#xD;
        -  To compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  To compare the toxicity burden of these regimens in these patients.&#xD;
&#xD;
        -  To compare the OS and PFS according to patients' peritoneal surface tumor genotype for&#xD;
           the NAD(P)H (quinone oxidoreductase 1 [NQO1] 609C &gt;T polymorphism [wild type vs&#xD;
           heterozygous/homozygous mutant]) in patients treated with these regimens.&#xD;
&#xD;
        -  To compare circulating tumor cells in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to presentation&#xD;
      (synchronous vs metachronous carcinomatosis), ECOG performance status (0 vs 1), disease&#xD;
      volume (measurable vs non-measurable), prior first-line therapy for advanced disease&#xD;
      (chemo-na√Øve vs prior first-line therapy), planned chemotherapy (oxaliplatin vs irinotecan vs&#xD;
      fluorouracil/leucovorin calcium vs capecitabine), and planned biologic therapy (bevacizumab&#xD;
      vs cetuximab vs none). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive standard systemic therapy, at the discretion of patients'&#xD;
           oncologist, comprising combinations of fluorouracil, leucovorin calcium, irinotecan&#xD;
           hydrochloride, oxaliplatin, and/or capecitabine (including FOLFOX4, mFOLFOX6, CapeOx, or&#xD;
           FOLFIRI) with or without bevacizumab (beginning 4-6 weeks after major surgery) or&#xD;
           cetuximab*. Treatment repeats in the absence of disease progression or unacceptable&#xD;
           toxicity. Patients with progressive disease may crossover to arm II.&#xD;
&#xD;
      NOTE: *For patients with KRAS wild-type tumors.&#xD;
&#xD;
        -  Arm II: Patients undergo cytoreduction surgery and hyperthermic intraperitoneal&#xD;
           mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive&#xD;
           standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6&#xD;
           courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood and tissue samples may be collected from patients for correlative studies.&#xD;
&#xD;
      Patients complete SF-36 Health Survey; Functional Assessment of Cancer Therapy-Colorectal&#xD;
      (FACT-C); Feeling Sad, Down, or Depressed (CES-D); and a Brief Pain Inventory quality-of-life&#xD;
      questionnaires at baseline and then periodically during study.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity burden</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of OS and PFS according to patients' peritoneal surface tumor genotype for the NAD(P)H</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard systemic therapy, at the discretion of patients' oncologist, comprising combinations of fluorouracil, leucovorin calcium, irinotecan hydrochloride, oxaliplatin, and/or capecitabine (including FOLFOX4, mFOLFOX6, CapeOx, or FOLFIRI), bevacizumab, or cetuximab. Treatment repeats in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo cytoreduction surgery and hyperthermic intraperitoneal mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
    <description>Given intraperitoneally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Patients undergo cytoreductive surgery</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colon adenocarcinoma meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
               -  Confirmed synchronous or metachronous limited peritoneal disease dissemination&#xD;
&#xD;
               -  No appendiceal or rectal cancer&#xD;
&#xD;
               -  No signet ring cell type&#xD;
&#xD;
          -  Disease amenable to complete cytoreduction surgery as indicated by:&#xD;
&#xD;
               -  Peritoneal Cancer Index (PCI) ‚â§ 20 by helical CT scan and/or staging laparoscopy&#xD;
&#xD;
               -  No parenchymal hepatic metastases&#xD;
&#xD;
               -  No clinical (jaundice), biochemical (abnormally elevated serum bilirubin and/or&#xD;
                  alkaline phosphatase), or radiological (by ultrasound, CT scan, or MRI) biliary&#xD;
                  obstruction&#xD;
&#xD;
               -  No symptomatic malignant ascites requiring palliative paracentesis&#xD;
&#xD;
               -  Small volume of disease in the gastro-hepatic ligament defined by a &lt; 5 cm mass&#xD;
                  in the epigastric region on cross-sectional imaging&#xD;
&#xD;
               -  No cross-sectional imaging findings indicative of multi-segmental (&gt; 1 site)&#xD;
                  small bowel obstruction, small bowel loops matted together, or gross disease of&#xD;
                  the small bowel mesentery characterized by distortion, thickening, or loss of&#xD;
                  mesenteric vascular clarity&#xD;
&#xD;
               -  No clinical or radiological evidence of hematogenous or distant nodal&#xD;
                  (retroperitoneal, pelvic, mediastinal, peri-portal, or peri-aortic) metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  ANC &gt; 1,200/mm¬≥&#xD;
&#xD;
          -  WBC &gt; 4,000/mm¬≥&#xD;
&#xD;
          -  Platelet count 150,000/mm¬≥&#xD;
&#xD;
          -  INR ‚â§ 1.5&#xD;
&#xD;
               -  Patients on therapeutic anticoagulant for unrelated medical condition such as&#xD;
                  atrial fibrillation or anti-thrombocyte treatment allowed provided treatment can&#xD;
                  be withheld for operation&#xD;
&#xD;
          -  Total serum bilirubin ‚â§ 1.5 mg/dL (&gt; 1.5 mg/dL for patients with Gilbert syndrome)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST &lt; 1.5 times ULN&#xD;
&#xD;
          -  Serum creatinine normal&#xD;
&#xD;
          -  BUN normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of severe congestive heart failure or severe pulmonary disease&#xD;
&#xD;
               -  Patients who are status post-revascularization procedures with satisfactory&#xD;
                  cardiac function are eligible&#xD;
&#xD;
          -  No acute myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No significant history of a medical problem or co-morbidity (e.g., severe congestive&#xD;
             heart failure or active ischemic heart disease) that would preclude a major abdominal&#xD;
             operation&#xD;
&#xD;
          -  No concurrent second malignancy requiring systemic therapy&#xD;
&#xD;
          -  No psychiatric or addictive disorders, or other conditions that would preclude the&#xD;
             patient from meeting the study requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior second-line systemic treatment for metastatic colon adenocarcinoma&#xD;
&#xD;
               -  Patients who received prior adjuvant therapy for colon adenocarcinoma and/or&#xD;
                  prior first-line systemic therapy for metastatic colon adenocarcinoma are&#xD;
                  eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Stojadinovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Agnes Hospital Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>January 21, 2012</last_update_submitted>
  <last_update_submitted_qc>January 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2012</last_update_posted>
  <responsible_party>
    <name_title>Alexander Stojadinovic</name_title>
    <organization>Walter Reed Army Medical Center</organization>
  </responsible_party>
  <keyword>mucinous adenocarcinoma of the colon</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

